The inhibition of acetylcholinesterase by irinotecan and related camptothecins: Key structural properties and experimental variables

Anti-Cancer Drug Design

Volumn 16, Issue 4-5, 2001, Pages 239-246

  Dodds, Helen M ^a,b   Hanrahan, Jane ^a   Rivory, Laurent P ^a,b  

^a University of Sydney   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

4 PP; Acetylcholinesterase; APC; Camptothecin; CPT; CPT 11; Inhibition; Irinotecan; N methyl CPT 11 piperidinium iodide; NPC

Indexed keywords

ACETYLCHOLINESTERASE; CAMPTOTHECIN; CARBOXYLIC ACID; DNA TOPOISOMERASE; IRINOTECAN; LACTONE; PIPERIDINE DERIVATIVE;

ARTICLE; DEACYLATION; DRUG POTENCY; DRUG STRUCTURE; EEL; ENZYME ASSAY; ENZYME INHIBITION; ENZYME KINETICS; KINETICS; LIGAND BINDING; PRIORITY JOURNAL; SUBSTITUTION REACTION; SYNTHESIS;

ACETYLCHOLINESTERASE; ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING, COMPETITIVE; CAMPTOTHECIN; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, LIQUID; DEALKYLATION; ELECTROPHORUS; KINETICS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

ANGUILLIFORMES; ELECTROPHORUS ELECTRICUS;

EID: 0035437386     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Belleau B., DiTullio V., Tsai Y.H. (1970) Kinetic effects of leptocurares and pachycurares on the methanesulfonylation of acetylcholinesterase. A correlation with pharmacodynamic properties. Molecular Pharmacology, 6, 41.
2. Berman H.A., Decker M.M., Nowak M.W., Leonard K.J., McCauley M., Baker W.M., Taylor P. (1987) Site selectivity of fluorescent bisquaternary phenanthridinium ligands for acetylcholinesterase. Molecular Pharmacology, 31, 610.
3. Cassidy C.S., Lin J., Frey P.A. (1997) A new concept for the mechanism of action of chymotrypsin: The role of the low-barrier hydrogen bond. Biochemistry, 36, 4576.
4. Dodds H.M., Rivory L.P. (1999) The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Molecular Pharmacology, 56, 1346.
5. Dodds H.M., Craik D.J., Rivory L.P. (1997) Photodegradation of irinotecan (CPT-11) in aqueous solutions: Identification of fluorescent products and influence of solution composition. Journal of Pharmaceutical Sciences, 86, 1410.
6. Dodds H.M., Clarke S.J., Findlay M., Bishop J.F., Robert J., Rivory L.P. (2000) Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. Cancer Chemotherapy and Pharmacology, 45, 9.
7. Gandia D., Abigerges D., Armand J-P., Chabot G., Da Costa L., De Forni M., Mathieu-Boue A., Herait P. (1993) CPT-11 induced cholinergic effects in cancer patients [letter]. Journal of Clinical Oncology, 11, 196.
8. Kawato Y., Sekiguchi M., Akahane K., Tsutuomi Y., Hirota Y., Kuga H., Suzuki W., Hakusui H., Sato K. (1993) Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. Journal of Pharmacy and Pharmacology, 45, 444.
9. Kim D.K., Ryu D.H., Lee J.Y., Lee N., Kim Y.W., Kim J.S., Chang K., Im G.J., Kim T.K., Choi W.S. (2001) Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues. Journal of Medicinal Chemistry, 44, 1594.
10. Lackey K., Sternbach D.D., Croom D.K., Emerson D.L., Evans M.G., Leitner P.L., Luzzio M.J., McIntyre G., Vuong A., Yates J., Besterman J.M. (1996) Water soluble inhibitors of topoisomerase I: Quaternary salt derivatives of camptothecin. Journal of Medicinal Chemistry, 39, 713.
11. Massiah M.A., Viragh C., Reddy P.M., Kovach I.M., Johnson J., Rosenberry T.L., Mildvan A.S. (2001) Short, strong hydrogen bonds at the active site of human acetylcholinesterase: Proton NMR studies. Biochemistry, 40, 5682.
12. Mooser G., Sigman D.S. (1972) Identification of a modifier site on acetylcholinesterase with affinity for d-tubocurarine. Biochemical and Biophysical Research Communications, 48, 559.
13. Perrin D.D., Amarego W.L.F. (1988) Purification of Laboratory Chemicals. Pergamon Press: Oxford.
14. Riddles P.W., Blakeley R.L., Zerner B. (1979) Ellman's reagent: 5,5′-Dithiobis(2-nitrobenzoic acid) - A reexamination. Analytical Biochemistry, 94, 75.
15. Rivory L.P., Riou J-E, Haaz M.-C., Sable S., Vuilhorgne M., Commerçon A., Pond S.M., Robert J. (1996) Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Research, 56, 3689.
16. Rothenberg M.L., Kuhn J.G., Burris H.A., Nelson J., Eckardt J.R., Tristan-Morales M., Hilsenbeck S.G., Weiss G.R., Smith L.S., Rodriguez G.I., Rock M.K., Von Hoff D.D. (1993) Phase I and pharmacokinetic trial of weekly CPT-11. Journal of Clinical Oncology, 11, 2194.
17. Taylor P., Lwebuga-Mukasa J., Lappi S., Rademacher J. (1974) Propidium - A fluorescence probe for a peripheral anionic site on acetylcholinesterase. Molecular Pharmacology, 10, 703.
18. Valencak J., Raderer M., Kornek G.V., Henja M.H., Scheithauer W. (1998) Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin [letter]. Journal of the National Cancer Institute, 90, 160.